« Merck Serono’s Phase III Diet Study of Phenoptin for Phenylketonuria Yielded Positive Results | Main | Denderon Corp.’s BLA for PROVENGE® under USFDA Priority Review Status for the Treatment of Asymptomatic, Metastatic, Androgen-Independent Prostate Cancer »

Jan17
XTL and DOV Pharmaceuticals, Agreed on Worldwide Rights to Bicifadine

XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, LON: XTL) signed an agreement with DOV Pharmaceutical, Inc. (OTC: DOVP) to in-license the worldwide rights for Bicifadine.

Bicifadine is a serotonin and norepinephrine reuptake inhibitor (SNRI) that XTL intends to develop for the treatment of neuropathic pain - a chronic condition resulting from damage to peripheral nerves.

Compared to the currently approved SNRI's, Bicifadine has a unique ratio of serotonin versus norepinephrine reuptake inhibition, which is weighted toward norepinephrine reuptake inhibition, providing a strong scientific rationale for using Bicifadine for the treatment neuropathic pain indications.

XTLBio.gifPrevious clinical trials have shown that Bicifadine is safe and generally well tolerated.

The terms of agreement include:

  • XTL will make an up-front payment of $7.5 million in cash. In addition, XTL will make milestone payments of up to $126.5 million, in cash and/or XTL ordinary shares over the life of the license, of which up to $115 million will be due upon or post approval of the product.
  • XTL is also obligated to pay royalties on net sales of the product to DOV. In addition, the Company has committed to pay a transaction advisory fee in the form of stock appreciation rights in the amount equivalent to 3% of the Company's current fully diluted ordinary shares, vesting after one year of the close of the transaction, and 7% of the Company's current fully diluted ordinary shares, vesting following successful Phase 3 clinical trial results or the acquisition of XTL.
  • Payment of the stock appreciation rights by XTL can be satisfied, at XTL's discretion, in cash and/or by issuance of the Company's ordinary shares.
Source: XTL Biopharmaceuticals Ltd.

related entries


0 Comments/Trackbacks




submit a trackback

TrackBack URL for this entry:

post a comment

Name, Email Address, and URL are not required fields.





Comment Preview

« Merck Serono’s Phase III Diet Study of Phenoptin for Phenylketonuria Yielded Positive Results | Main | Denderon Corp.’s BLA for PROVENGE® under USFDA Priority Review Status for the Treatment of Asymptomatic, Metastatic, Androgen-Independent Prostate Cancer »

Advertise

Watch the Digital Health Revolution


Related Resources

recent comments

    sponsored ads



    subscribe


    Prefer Email?
    Subscribe below-

    Enter your Email:


    Powered by FeedBlitz What's this?

    Current News

    Support This Blog

    blogroll


    top blogs

    business social media

    Use these fast growing business social media sites to promote your business, feature your products, spotlight your business leaders, create links, and drive traffic back to your company site, all for free!

    BIZZlogos - Add your logo - free link to your site
    BIZZphotos - Add photos of your products and people
    BIZZprofiles - Submit your profile and build your online visibility
    BIZZspotlight - Spotlight your business with free links
    BIZZvideos - Videos about businesses, products and business people.
    BIZZbites - "Digg" for Business - Submit your articles and posts

    Know More Media - Health Care / Pharmaceutical / Fitness

    know more media network

    View Network Map

    Network Feed List (OPML)

    Know More Media Network
    Feed


    we support unitus

    PRWeb

    Influencer



    PharmaGazette is a member of the Know More Media network of business related blogs.

    Here are some current headlines from some of our business publications:

    ProductivityGoal

    CallCenterScript

    AdHurl

    TheBizofKnowledge

    LandingTheDeal

    CustomersAreAlways

    HealthCareVox

    BrainBasedBusiness

    TheInsurancePolicy

    MarketingBlurb